Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…